公开(公告)号：US20230113262A1

公开(公告)日：2023-04-13

申请号：US17818874

申请日：2022-08-10

Applicant: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY

Inventor： Jae Hyung PARK ,  Joshua Alexander JACKMAN ,  Hyewon KO ,  Sol SHIN ,  Bo Kyeong YOON ,  Chanho KIM ,  Soyoung SON

IPC: A61K39/00 ,  C07K14/705

Abstract: The present invention relates to a peptide for cancer immunotherapy that disrupts tumor-derived vesicles and a use thereof. The peptide according to the present invention has an α-helical structure, inhibits T-cell functional impairment caused by tumor-derived vesicles and controls the formation of a tumor microenvironment as an immunosuppressive environment by disrupting the tumor-derived vesicles, and has effects of not only enhancing cancer immunotherapy activity but also inhibiting the metastasis of cancer cells through co-administration with an immune checkpoint inhibitor. Additionally, when the peptide is modified with PEG through a pH-sensitive linker, it has effects of increasing the stability of the peptide in vivo, and disrupting tumor-derived vesicles under the pH condition of the tumor microenvironment. Accordingly, the peptide of the present invention is expected to be effectively used in a composition for cancer immunotherapy, a composition for enhancing the sensitivity of cancer immunotherapy, or the composition for inhibiting cancer metastasis.